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874Objectives: Aortic or pulmonary homografts (A/PHs) are common biomaterials used for restoration of right
ventricle to pulmonary artery continuity for repair of various congenital heart defects. The smaller sized
homografts required for early primary repair in neonates and infants are prone to early failure and are in short
supply. Due to these limitations, since 2008 it has been our preference to use valved segments of cryopreserved
femoral vein homograft (cFVH) for right ventricle to pulmonary artery reconstruction. This study was
undertaken to assess the performance of cFVH compared with A/PH in neonates and infants.
Methods: A retrospective review of all infants and neonates who underwent biventricular early primary repair
with right ventricle to pulmonary artery reconstruction using homograft conduits at a single center was
conducted. Patients who received cFVH constituted the study group, whereas all other patients received
A/PH and formed the control group. Patients with pulmonary atresia, ventricular septal defect, and major
aortopulmonary collaterals who had conduits placed to promote pulmonary artery growth or to unifocalized
pulmonary vasculature were excluded from the study because they have different clinical indications for
reoperation and reintervention. Demographic, anatomical, perioperative, and follow-up variables were
compared between the groups using univariate and multivariable Cox regression analyses. Kaplan-Meier
analysis and log-rank tests were used to identify intergroup differences in freedom from catheter intervention,
reoperation, or overall freedom from reintervention (catheter and/or surgical).
Results: A total of 36 patients (20 cFVH and 16 A/PH) were included in the study. There were no intergroup
differences in the demographic, anatomic, and perioperative variables, except for significantly shorter aortic
crossclamp time in the cFVH group. Univariate analysis revealed a higher catheter reintervention rate as well
as higher reoperation rate in the A/PH group. Multivariate Cox regression correcting for the intergroup
differences in the length of follow-up revealed comparable freedom from catheter intervention, freedom from
reoperation, or freedom from either intervention in the cFVH and the A/PH groups.
Conclusions: Valved femoral vein homografts have comparable short- and intermediate-term performance to
A/PHs for right ventricular outflow tract reconstruction and are an attractive alternative to other small conduits
for use in neonates and infants. (J Thorac Cardiovasc Surg 2014;147:874-9)Consistent with the general trend toward early primary
repair, right ventricular outflow tract (RVOT) reconstruc-
tion with a conduit is increasingly used in neonates and
infants.1,2 Current surgical options for conduits for these
small patients with complex disease include aortic3 or
pulmonary homografts4 (A/PHs) and bovine jugular vein
grafts (Contegra; Medtronic Inc, Minneapolis, Minn), all
of which have the drawback of early failure, especially
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The Journal of Thoracic and Cardiovascular Surgpopulation.5-7 A/PHs are also in short supply in the small
size ranges required for neonates and infants and are
considerably more expensive than cryopreserved femoral
vein homografts (cFVHs). Pericardial conduits can be
limited by the availability of suitable autologous
pericardium and the need for additional personnel and
operative time for fabrication, and do not offer better
conduit durability.8
For all of the above reasons it has been our preference to
use cFVH for RVOT reconstruction since 2008.9 Here we
report our intermediate-term cumulative experience in
neonatal and infant RVOT reconstruction with this novel
alternative conduit.
METHODS
Awaiver of documented consent was granted by the Children’s National
Medical Center Institutional Review Board due to the retrospective nature
of the study. Data on all neonates and infants (aged <1 year) who
underwent a single-stage biventricular repair of congenital heart disease
using cFVH as a valved right valve to pulmonary artery (RV-PA) conduit
between July 2008 and December 2012 (cFVH group) were retrospectively
reviewed. The control group consisted of children with similar heartery c March 2014
Abbreviations and Acronyms
A/PH ¼ aortic or pulmonary homograft
cFVH ¼ cryopreserved femoral vein homograft
RVOT ¼ right ventricular outflow tract
RV-PA ¼ right ventricle to pulmonary artery
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Ddefects, matched by age and weight, who had A/PH used for RV-PA
reconstruction before July 2008 (A/PH group). Patients with pulmonary
atresia, ventricular septal defect, and major aortopulmonary collaterals
who had conduits placed to promote pulmonary artery growth or
unifocalized pulmonary vasculature were excluded from the study because
they have different clinical indications for reoperation and reintervention.
Demographic, preoperative, intraoperative, postoperative, and follow-up
data were recorded and compared between the 2 groups. The primary
end points were conduit catheter reinterventions (percutaneous interven-
tion on the conduit), conduit reoperations (surgical replacement/revision),
or both. Intraoperative and immediate postoperative variables constituted
the secondary end points.
Operative Technique
All patients underwent biventricular complete intracardiac repair and
RVOT reconstruction via a median sternotomy with hypothermic
cardiopulmonary bypass support. Deep hypothermic circulatory arrest was
performed only when aortic arch reconstruction was required. RVOT recon-
struction was performed using a valved segment of cFVH (cFVH group) or
A/PH (A/PH group). The operative technique has been described in our
previous report.9 After selecting an appropriately sized segment with a
competent valve, maintaining antegrade orientation, the distal anastomosis
to the pulmonary artery bifurcationwas fashioned using continuous 6-0 poly-
propylene sutures. The proximal end of the graft was spatulated posteriorly
and anastomosed to the right ventriculotomy using a running 5-0 polypro-
pylene suture. No hoods were necessary to augment the proximal
anastomosis. Primary sternal closure was performed whenever possible.
In theA/PHgroup,A/PHswere used to reconstruct theRVOTusing stan-
dard techniques, including a pericardial hood at the proximal anastomosis.
Additional procedureswere performed as indicated by the cardiac anatomy.
The indication for catheter- or surgical-based reintervention was
severe conduit stenosis, insufficiency, or a combination of moderate
stenosis and moderate conduit insufficiency as determined either by
echocardiogram or hemodynamic cardiac catheterization, and was similar
for both groups.
Statistical Analysis
Univariate analysis was performed to compare demographic,
perioperative, and follow-up data between the 2 groups. Continuous data
are presented as median (interquartile range) and were compared using the
Mann-Whitney U test. Proportions were compared using the Fisher exact
test and categorical data by the c2 test. Follow-up data were analyzed for
freedom from catheter intervention, reoperation (surgical conduit revision/
replacement), or overall freedom from any reintervention (catheter and/or
surgical) using Kaplan-Meier analysis with the log-rank test to identify
intergroup differences. Multivariate Cox regression was applied to compare
time to catheter intervention or surgical reintervention controlling for conduit
diameter and length of follow-up as covariates. Datawas analyzed using IBM
SPSS Statistics version 19.0 (IBM-SPSS Inc, Armonk, NY).RESULTS
Between July 1998 and July 2012, 36 patients younger
than age 1 year underwent 1 stage complete biventricularThe Journal of Thoracic and Carepair using a RV-PA conduit. Twenty patients (mean
weight, 3.4 kg; mean age, 36 days) underwent
RVOT reconstruction using a cFVH, whereas 16 infants
(mean weight, 3.4 kg; mean age, 24 days) underwent
placement of aortic (n ¼ 5) or pulmonary (n ¼ 11) homo-
graft for restoration of RV-PA continuity. Demographic,
operative, and postoperative data are detailed in Table 1.
We switched to using the cFVH in 2008; therefore, all
patients in the study group were operated on between
2008 and 2012, whereas the control group underwent
surgery before 2008. The 2 groups were comparable for
demographic, anatomic, and perioperative variables, except
for a significantly shorter mean aortic crossclamp time for
the cFVH group (cFVH group, 64 minutes; A/PH group,
81 minutes; P ¼ .04). There were 2 operative mortalities
(defined as occurring on the same admission or <30
postoperative days) in the cFVH group, 1 due to a stroke
>2 weeks after conduit placement in a patient with truncus
arteriosus with interruption of the aortic arch, and the other
secondary to refractory postoperative low cardiac output
and hypoxic ischemic encephalopathy in a patient with
truncus arteriosus with interrupted aortic arch and severe
truncal valve insufficiency who underwent complete repair.
There were no operative deaths in the control group
(Table 1). There were 2 late deaths in the cFVH group,
both of them unrelated to the conduit. One patient with
double outlet right ventricle, subpulmonic ventricular septal
defect, aortic stenosis, severely hypoplastic ascending
aorta, and interrupted aortic arch who underwent a Yasui
repair died due to respiratory arrest of unknown etiology
9 months after surgery. The other patient had pulmonary
atresia with ventricular septal defect and multiple
extracardiac anomalies, and died of late complications
from esophageal stenosis after tracheoesophageal fistula
repair 8 months after the cardiac procedure. No late
mortality occurred in the A/PH group.
One of 18 patients was lost to follow-up in cFVH group
for a follow-up rate of 94% (17 out of 18), whereas
follow-up was 100% in the A/PH group (16 out of 16).
The length of follow-up was significantly longer in the
A/PH group (mean, 354 [range, 150-731] days in the
cFVH group and mean, 1527 [range, 562-2138] days in
the A/PH group; P ¼ .01). On univariate analysis a lower
need for catheter reinterventions was seen in the cFVH
group compared with the A/PH group (6 [35%] vs 13
[81%]) requiring a total of 7 and 29 interventional cardiac
catheterizations, respectively (P ¼ .01). The need for
surgical conduit reoperation was similarly lower in the
cFVH group than in the A/PH group (2 [12%] vs
9 [56%]; P ¼ .01). The time to conduit change after
conduit placement was comparable in both groups
(602 [range, 497-815] days and 963 [range, 700-1916]
days for cFVH and A/PH groups, respectively; P ¼ .22)
(Table 2). Kaplan-Meier analysis with log-rank testrdiovascular Surgery c Volume 147, Number 3 875
TABLE 1. Demographic, operative, and postoperative data of the 2
study groups
Variable
cFVH
group
(n ¼ 20)
A/PH
group
(n ¼ 16) P
Demographic and anatomical data
Male gender 13 (65) 6 (38) .18
Prematurity (<37 wk) 3 (17)* 2 (17)* 1
Low birth weight (2.5 kg) 3 (15) 2 (13) 1
Confirmed DiGeorge syndrome 1 (5) 5 (31) .07
Confirmed prenatal diagnosis 8 (40) 5 (31) .73
Anatomical diagnosis .50
Truncus arteriosus 6 (30) 9 (56)
TOF with pulmonary atresia 7 (35) 4 (25)
Truncus arteriosus with IAA 2 (10) 1 (6.3)
DORV including Taussig-Bing
anomaly
3 (15) 0 (0)
Aortic atresia with IAA and VSD 1 (5) 1 (6.3)
TGAwith PS 1 (5) 1 (6.3)
Preoperative mechanical ventilation 7 (35) 3 (23)y .70
Preoperative inotropic support 5 (25) 0 (0)y .13
Operative parameters
Age at operation, d 13 (7-48) 11 (7-40) .93
Weight at operation, kg 3.4  1.0 3.4  0.7 .52
Conduit diameter, mm 10.7  1.1 10.6  1.6 .87
Cardiopulmonary bypass time, min 121  37 148  60 .11
Crossclamp time, min 64  29 81  18 .06
Deep hypothermic cardiac arrest 8/20 (40) 5/16 (31) .73
Type of operative procedure .39
Truncus arteriosus repair 5 (25) 9 (56)
Truncus arteriosus repair with
aortic arch reconstruction
3 (15) 1 (6.3)
Modified Yasui procedure 3 (15) 1 (6.3)
Rastelli procedure 9 (45) 5 (31)
Delayed chest closure 11 (55) 4 (27) .10
RACHS-1 category 4 (3-5) 4 (3-5) .94
Postoperative parameters
Mechanical ventilation duration, d 6 (3-13) 5 (2-6) .18
Inotropic support duration, d 7 (4-17) 5 (2-9) .16
Extracorporeal membrane
oxygenator support
1 (5) 0 (0) 1
Complications
Bleeding 1 (5) 1 (7)z 1
Arrhythmia requiring treatment 5 (25) 7 (50)z .16
Seizures 1 (5) 2 (14)z .56
Cardiac intensive care unit length of
stay, d
15 (8-34) 11 (5-15) .17
Hospital length of stay, d 32 (13-54) 16 (15-33) .16
Operative mortality 2 (10) 0 (0) .49
Values are presented as n (%), median (interquartile range), or mean  standard
deviation. cFVH, Cryopreserved femoral vein homograft; A/PH, aortic/pulmonary
homograft; TOF, tetralogy of Fallot; IAA, interrupted aortic arch; DORV, double
outlet right ventricle; VSD, ventricular septal defect; TGA, transposition of the great
arteries; PS, pulmonary stenosis; RACHS-1, Risk Adjustment for Congenital Heart
Surgery 1. *n ¼ 18 patients for cFVH group, n ¼ 12 patients for A/PH group.
yn ¼ 13. zn ¼ 14.
TABLE 2. Follow-up data of the 2 study groups
Variable
cFVH
group
(n ¼ 17)
A/PH
group
(n ¼ 16) P
Median follow-up, d 354 (150-731) 1527 (562-2138) .01*
Catheter reinterventions
Patients 6 (35) 13 (81) .01*
Interventional catheterizations,% 7 29
Original conduit to first
catheterization, d
169 (104-480) 191 (118-407) .64
Conduit reoperations (conduit
replacement/revisions)
Patients 2 (12) 9 (56) .01*
Time from original conduit to
replacement, d
602 (497-815) 963 (700-1916) .22
Overall reinterventions (catheter-
based interventions or
reoperation)
8 (47) 13 (81) .07
Patients still with original conduit 15 (88) 7 (44) NS
Echocardiographic findings
Significant conduit stenosis 1 (7) 1 (14)
Significant conduit insufficiency 3 (20) 0 (0) .52
Mixed conduit disease 1 (7) 0 (0) NS
Late mortality 2 (12) 0 (0) NS
Conduit reoperations 2 (12) 9 (56) .01*
Indication for reoperation
Severe conduit stenosis  mild
insufficiency
1 (50) 2 (22) .48
Severe conduit insufficiency 
mild stenosis
0 0 (0) NS
Moderate/severe conduit stenosis
and moderate/severe conduit
insufficiency
1 (50) 7 (78) .49
Values are presented as n (%) or median (interquartile range). cFVH, Cryopreserved
femoral vein homograft; A/PH, aortic/pulmonary homograft; NS, nonsignificant.
*Statistically significant.
Congenital Heart Disease Schiller et al
C
H
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(P ¼ .12) and lower overall reintervention (P ¼ .35) in876 The Journal of Thoracic and Cardiovascular Surgthe cFVH group compared with the A/PH group, although
the differences were not significant (Figures 1-3).
Multivariable Cox regressionmodel adjusting for conduit
diameter and differences in length of follow-up revealed
comparable need for catheter intervention (P ¼ .12), need
for surgical reintervention (P ¼ .83), and overall freedom
from reinterventions (P ¼ .74) between the cFVH and
A/PH groups (Table 3). Mixed conduit disease was the
predominant indication for reoperation in both groups
(Table 2).
DISCUSSION
This is the first study reporting outcomes of the cFVH for
early primary repair requiring RV-PA continuity restoration.
Our study shows a trend toward lower catheter and overall
reintervention rates in this patient population of neonates
and infants, a group otherwise known to require early
reintervention for conduit disease.
cFVHs have the advantage of being widely available
from adult cadaver donors in contrast to small sizeery c March 2014
FIGURE 1. Kaplan-Meier curves illustrating freedom from catheter reintervention for the cryopreserved femoral vein homograft (cFVH) and aortic or
pulmonary homograft (A/PH) groups. Top, Number of patients at risk and available for analysis for cFVH. Bottom, Number of patients at risk and available
for analysis for A/PH.
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DA/PHs, which are usually supplied by rare pediatric donors.
Adult cFVHs (provided by Cryolife Inc, Kensaw, Ga, or
LifeNet Health, Virginia Beach, Va) are available in 25-
to 30-cm length segments, with the diameter tapering
from approximately 15 mm to 9 mm (ideal size rangeFIGURE 2. Kaplan-Meier curves showing freedom from conduit reoperation
(cFVH) and aortic or pulmonary homograft (A/PH) groups. Top, Number of patie
at risk and available for analysis for A/PH.
The Journal of Thoracic and Carequired for neonates or infants), whereas the shortage in
A/PHs is most marked. The femoral vein homograft
segments have 2 to 4 competent valves across their length,
giving the surgeon a choice in selecting the appropriately
sized valved segment. The material is thin walled ands (surgical reintervention) for the cryopreserved femoral vein homograft
nts at risk and available for analysis for cFVH. Bottom, Number of patients
rdiovascular Surgery c Volume 147, Number 3 877
FIGURE 3. Kaplan-Meier curves of freedom from overall reintervention (catheter and/or surgical) for the cryopreserved femoral vein homograft (cFVH)
and aortic or pulmonary homograft (A/PH) groups. Top, Number of patients at risk and available for analysis for cFVH. Bottom, Number of patients at risk
and available for analysis for A/PH.
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Dideally suited for anastomosis to the delicate thin walled
distal pulmonary artery bifurcation in infants and neonates.
Despite being thin walled it is hemostatic and can be
directly anastomosed to the right ventricular incision
without a hood, simplifying the technical aspects of the
operation. These technical advantages account for the
significantly shorter aortic crossclamp time in the cFVH
group in this series. The femoral vein homograft is also
considerably cheaper compared with the other alternatives,
and with appropriate isolation and packaging of the vein
segments (eg, isolating individual valved segments by
vendors) have the potential for further cost savings.
Although pulmonary homografts may be preferred for
RVOT reconstruction due to lower calcification rate andTABLE 3. Results of multivariable time-to-event Cox model for each
outcome: Comparison of surgical technique adjusted for conduit
diameter and follow-up time
Covariate
Catheter
reinterventions
Conduit
reoperations
Overall
reinterventions
(catheter and/ or
surgical
reintervention)
cFVH vs A/PH
technique
.33 .88 .35
Conduit diameter,
mm
.43 .12 .19
Follow-up, mo .13 .83 .74
Values are P values. cFVH, Cryopreserved femoral vein homograft; A/PH, aortic/pul-
monary homograft.
878 The Journal of Thoracic and Cardiovascular Surgconduit failure rate compared with aortic homografts,10 in
the neonatal and infant age group the choice of conduit is
often dictated by the availability of an appropriately sized
conduit. Additionally, use of smaller A/PHs has been shown
to increase the rate of conduit failure and the reoperation
rate.1,11 Although downsizing (or bicuspidization) of a
larger homograft12,13 is an option to circumvent the
shortage of smaller conduits, the resultant conduit is still
thick walled, posing a mismatch to the delicate thin-
walled pulmonary arteries found in neonates and infants
and requires additional personnel and operating time.14,15
Bovine jugular vein grafts have shown variable results16,17
and similar to theA/PHs have a higher intervention rate in the
smaller size ranges (ie, 12-16 mm).18-22
Despite our study being a retrospective, single-center re-
view of patients with short- to intermediate-term follow-up,
and historical controls, femoral vein homografts have been
shown to be comparable to A/PHs for early primary repair
and RVOT reconstruction in neonates and infants, with a
trend toward lower catheter and overall reintervention rates.
These comparable results hold after adjustment for
differences in follow-up. Larger studies with longer
follow-up will be required to further study the potential
long-term advantages of this attractive conduit.CONCLUSIONS
Our study shows that cFVH has a comparable periopera-
tive course and short and intermediate outcome compared
with A/PH for RV-PA continuity restoration in newbornsery c March 2014
Schiller et al Congenital Heart Diseaseand infants, with a trend toward lower reintervention rates.
This novel technique offers an attractive alternative to other
small conduits for use in neonates and infants.C
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